Company – Scrape Financial
Risk Factors Summary

Risk Factors Update Summary

  • Added history of losses. This change highlights a significant financial risk for investors.
  • Phase 2/3 clinical testing status updated for NRX-101. This change impacts product development timelines.
  • Increased Phase 2 clinical trial sites for NRX-101 from one to two. This change affects trial progress.
  • Increased cash equivalents from approximately $20 million to $4 million. This change affects liquidity.
  • Phase 2/3 clinical testing status updated for NRX-101. This impacts the drug development timeline.
  • Net losses decreased from $93 million to $30 million. This change reflects improved financial performance.
  • Transition from Nasdaq Global Market to Nasdaq Capital Market. This change may impact stock liquidity.

Full Text Changes in Most Recent 10-K

Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.

To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1719406&owner=exclude

Click here to download the PDF

This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.